Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

Radiotherapy

 

Fremman buys Stingray to merge with Amethyst

Two of Europe’s three largest private oncology groups are being merged into a single entity, creating continental Europe’s largest oncology player. Private equity firm Fremman Capital has acquired Stingray, an oncology group with a presence in France and Germany, to merge it with its portfolio company Amethyst, a major pan-European radiotherapy group which already has a presence in seven European countries.

Amethyst enters Portugal

Pan-European oncology group Amethyst has entered the Portuguese market. It has acquired Júlio Teixeira, a private Portuguese oncology provider consisting of two clinics.

‘Saudization’ kickstarts in Saudi Arabia’s healthcare sector

The first phase of ‘Saudization’ in Saudi Arabia’s healthcare sector is now underway, effective from 17 April. Saudization is a government policy to increase the number of Saudi nationals employed and reduce the reliance on expats in the workforce. 

Healthcare investment “through the bottom of the cycle” — Goldberg (Rothschild)

At last year’s conference Hedley Goldberg, Managing Director at multinational investment bank Rothschild, predicted healthcare M&A activity would begin picking up again in Q4 2023 or Q1 2024. But we’re now halfway through 2024 and there are still very few deals above €500m taking place. Goldberg is confident, however, that we have now passed through the bottom of the cycle.

Find Us